about
Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesComparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.Osteoarthritis: an overview of the disease and its treatment strategies.The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study.The acromegalic arthropathy.Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study.Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey.Enteropathic spondyloarthritis: from diagnosis to treatment.The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.Italian evidence-based recommendations for the management of ankylosing spondylitis: the 3E Initiative in Rheumatology.The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infectionEtanercept in spondyloarthropathies. Part I: current evidence of efficacy.Etanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issues.Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis.Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs.Osteoporosis and psoriatic arthritis.Managing moderate-to-severe psoriasis in the elderly.Efficacy of tocilizumab in a patient with refractory psoriatic arthritis.Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease.The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis.Biological therapies for spondyloarthritis.Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.Measuring psoriatic disease in clinical practice. An expert opinion position paper.The Definition and Measurement of Axial Psoriatic Arthritis.Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Emerging drugs for psoriatic arthritis.Psoriatic arthritis and psoriasis: differential diagnosis.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients.Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-α therapy.Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement.Dactylitis in enteropathic spondyloarthritis.The classification of psoriatic arthritis: what will happen in the future?Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.Fragility Fractures in Patients with Psoriatic Arthritis.Psoriatic Disease: Clinical Staging.Trauma and seronegative spondylarthropathy.
P50
Q26777084-2FE5381C-C0E5-4BFA-A769-324E49BAACD4Q33387811-C5508304-D964-470C-AC66-DF47C532EFEDQ33659058-074BE939-E45F-4294-A3DE-50B771F991C7Q34440851-C72F3425-E488-4310-8F87-2AAD6185A2CDQ35132212-F1FB9DCD-96CE-43B7-8F96-867BDD667EBFQ36329244-1F4E00E2-88E8-473E-9F7F-AF548540058DQ36633179-CC35A367-D743-4E51-A5AF-5C47E5C04E16Q36758296-BCB10EFB-874E-400B-8267-404BE92D4917Q36830824-8BEF5C31-5F97-439A-ADDA-632B1ABDA602Q36940942-CAFF7587-B6CD-4BA2-B527-291AF9F80B71Q37390900-F4C2222B-9C04-4314-93CF-6515E8880EFFQ37655910-2819D222-438A-4336-8A8D-CB71C7165635Q37951219-88E0B063-A6E7-41E2-B1A1-09A6B42B49FAQ37951220-E667C9FD-5DDE-4334-B3C8-3E07055CD09AQ37991557-DCEF7A5F-797D-4185-A6C0-690954664392Q38018076-FD916A67-C9CD-4EFF-A386-7FF7FF893A83Q38023168-1B3DD45F-8165-4DE8-8F0D-F6830C23F2C6Q38189734-09FF9290-39B2-40C9-B4B5-3CE0E8F989D3Q38202538-069FE97C-725B-4997-B5C4-CB67ED754C47Q38204130-BBBBEEA0-5A1F-45B6-84C3-E8B654AD2FD7Q38213673-920D0ACC-6EE7-4297-A654-426AF434FACFQ38217223-C66EDA57-66A1-4AB3-A127-87BCBE1DF6C1Q38344512-E58D7AEE-4111-4978-8093-6D91311604D8Q38508340-097B3BAC-59EB-4A32-AD8F-3BDCBA57CDFFQ38622059-85658E1F-A9FA-4615-9039-59A9486B7512Q38622088-A3CD9745-95EA-40B1-8ADA-54B37A786C2EQ38630548-04ED27B1-8287-4E6B-96F9-DFD56EB3CEC7Q38710642-937C4638-3509-4DFC-89A4-0ECEB62BB420Q38828427-DAEACB36-9A24-41EF-8CBC-2AEA5BCE2446Q38856226-DB6A22BC-CACE-4CD4-81A9-C0B582257FE7Q39748097-31A82768-1984-4B9D-9316-CF8FCC8A7A6AQ39861020-8DD63B32-9DD1-441D-B5B9-23ED384CCE88Q39929264-CC683977-62CC-4CAA-B096-F9069FA88A7DQ40232466-E2711BA2-D112-4E7B-B482-E42276D3DAD0Q40795399-E6EE1754-45AD-41B9-A5F6-B0DD32CA6B8BQ40915943-15769709-7FBA-4262-B43B-3341D9BCFAA9Q41109448-F83B17BE-12CD-4810-B131-24D89A85DFC3Q41160242-36196690-B868-4051-9A39-7AB9EFBF2241Q41160257-E3A18F5B-362B-40FA-9E76-5EAF4F1D2EFCQ41229919-9B95959C-65E0-4C48-85DC-55199D26D0D1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Raffaele Scarpa
@ast
Raffaele Scarpa
@en
Raffaele Scarpa
@es
Raffaele Scarpa
@nl
type
label
Raffaele Scarpa
@ast
Raffaele Scarpa
@en
Raffaele Scarpa
@es
Raffaele Scarpa
@nl
prefLabel
Raffaele Scarpa
@ast
Raffaele Scarpa
@en
Raffaele Scarpa
@es
Raffaele Scarpa
@nl
P106
P1153
7101679872
P21
P31
P496
0000-0002-5808-6607